IL310894A - Milovacian for the prevention and treatment of thromboembolic disorders - Google Patents
Milovacian for the prevention and treatment of thromboembolic disordersInfo
- Publication number
- IL310894A IL310894A IL310894A IL31089424A IL310894A IL 310894 A IL310894 A IL 310894A IL 310894 A IL310894 A IL 310894A IL 31089424 A IL31089424 A IL 31089424A IL 310894 A IL310894 A IL 310894A
- Authority
- IL
- Israel
- Prior art keywords
- daily dose
- milvexian
- pharmaceutically acceptable
- acceptable salt
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245522P | 2021-09-17 | 2021-09-17 | |
| US202163278582P | 2021-11-12 | 2021-11-12 | |
| PCT/US2022/043797 WO2023043999A1 (en) | 2021-09-17 | 2022-09-16 | Milvexian for prevention and treatment of thromboembolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310894A true IL310894A (en) | 2024-04-01 |
Family
ID=83688923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310894A IL310894A (en) | 2021-09-17 | 2022-09-16 | Milovacian for the prevention and treatment of thromboembolic disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250099466A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4401736A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024534427A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240060820A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022345862A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232633A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024000776A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310894A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024002857A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202327607A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023043999A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4565231A1 (en) * | 2022-08-01 | 2025-06-11 | Bristol-Myers Squibb Company | Use of milvexian for treating or preventing ischemic stroke |
| CN121001727A (zh) * | 2023-04-19 | 2025-11-21 | 百时美施贵宝公司 | 米尔维仙(milvexian)于治疗及预防患有心血管或脑血管疾病的患者的血栓病况的用途 |
| CN121443289A (zh) * | 2023-04-19 | 2026-01-30 | 百时美施贵宝公司 | 米尔维仙在治疗或预防患有急性冠状动脉综合征的患者的不良脑血管事件或不良心血管事件中的用途 |
| CN121398811A (zh) * | 2023-04-19 | 2026-01-23 | 百时美施贵宝公司 | 米尔维仙于治疗及预防患有心房颤动的患者的血栓病况的用途 |
| WO2025126240A1 (en) * | 2023-12-12 | 2025-06-19 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions and use thereof |
| WO2026115567A1 (en) * | 2024-11-26 | 2026-06-04 | Dr. Reddy’S Laboratories Limited | Sustained release formulations of milvexian |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453018B2 (en) * | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| KR20210151183A (ko) | 2019-04-11 | 2021-12-13 | 브리스톨-마이어스 스큅 컴퍼니 | 치료 혈장 농도를 달성하기 위한 무정형 고체 및 가용화된 제제의 증진된 성능 |
-
2022
- 2022-09-16 JP JP2024516849A patent/JP2024534427A/ja active Pending
- 2022-09-16 IL IL310894A patent/IL310894A/en unknown
- 2022-09-16 KR KR1020247012366A patent/KR20240060820A/ko active Pending
- 2022-09-16 MX MX2024002857A patent/MX2024002857A/es unknown
- 2022-09-16 AU AU2022345862A patent/AU2022345862A1/en active Pending
- 2022-09-16 TW TW111135090A patent/TW202327607A/zh unknown
- 2022-09-16 CA CA3232633A patent/CA3232633A1/en active Pending
- 2022-09-16 WO PCT/US2022/043797 patent/WO2023043999A1/en not_active Ceased
- 2022-09-16 EP EP22786640.7A patent/EP4401736A1/en active Pending
- 2022-09-16 US US18/692,560 patent/US20250099466A1/en active Pending
-
2024
- 2024-03-15 CL CL2024000776A patent/CL2024000776A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250099466A1 (en) | 2025-03-27 |
| JP2024534427A (ja) | 2024-09-20 |
| KR20240060820A (ko) | 2024-05-08 |
| TW202327607A (zh) | 2023-07-16 |
| CA3232633A1 (en) | 2023-03-23 |
| CL2024000776A1 (es) | 2024-07-26 |
| AU2022345862A1 (en) | 2024-03-14 |
| MX2024002857A (es) | 2024-03-21 |
| WO2023043999A1 (en) | 2023-03-23 |
| EP4401736A1 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024534427A5 (cg-RX-API-DMAC7.html) | ||
| Shetty et al. | A prospective randomized study to analyze the efficacy of balanced pre-emptive analgesia in spine surgery | |
| US20080139667A1 (en) | Pharmaceutical Compositions For the Treatment of Disease and/or Symptoms in Arthritis | |
| KR100516676B1 (ko) | 안면 수술에서의 레보부피바카인의 용도 | |
| JP2017510607A5 (cg-RX-API-DMAC7.html) | ||
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| CA2313270A1 (en) | Use of deferiprone in treating and preventing iron-induced cardiac disease | |
| JP2016505050A5 (cg-RX-API-DMAC7.html) | ||
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤 | |
| KR20160080111A (ko) | 경추 및 요추 질환 치료용 약물 | |
| US9545419B1 (en) | Method and compositions for treating chronic inflammatory disorders | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| WO2025137652A3 (en) | Compositions comprising radiprodil and the use of radiprodil in the treatment of epileptic or neurobehavioral disorders | |
| KR102927058B1 (ko) | 진통 가려움 완화 약학 조성물 및 그 응용 방법 | |
| US6194460B1 (en) | Composition for treating cough induced by angiotensin converting enzyme inhibitors | |
| Sharma et al. | Comparative study of preclosure periportal instillation of three different concentrations of ropivacaine (0.125%, 0.25%, 0.5%) for postoperative analgesia in laparoscopic cholecystectomy | |
| Beute | (Oral) enoximone in asthma | |
| Sharma et al. | Efficacy and Safety of Transdermal versus Intravenous Diclofenac for Postoperative Analgesia in Pediatric Inguinal Surgeries: A Comparative Study | |
| CN107468917B (zh) | 一种化痰解毒治疗冠心病的中药组合物及其应用 | |
| WO2000050028A1 (en) | Compositions for the treatment of pain | |
| CN1682715A (zh) | 一种抗缺氧药物组合物 | |
| CN121550202A (zh) | 索法酮作为trpv3抑制剂在制备治疗皮肤疾病药物中的应用 | |
| CN113786433A (zh) | 一种用于骨性疾病疼痛的药物组方 | |
| WO2026107041A1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of pain | |
| CN120605308A (zh) | 珍宝丸在制备用于预防脑卒中的药物中的应用 |